| Cat.No. | Antigen | Neutralizing Activity | Affinity KD, nM | Application |
|---|---|---|---|---|
| TRB-Y1b | Trastuzumab F(ab')2 | Neutralizing Antibody | / |
PK bridging ELISA with TRB-Y5b Neutralizing assay Indirect ELISA |
| TRB-Y5b | Trastuzumab F(ab')2 | Neutralizing Antibody | / | PK bridging ELISA with TRB-Y1b |
| ADB-Y19 | Adalimumab F(ab')2 | Neutralizing Antibody | 0.0013 |
ADA assay Neutralizing assay Indirect ELISA |
| ADB-Y23b | Adalimumab F(ab')2 | Non-Neutralizing Antibody | / |
PK bridging ELISA with ADB-BY17 Indirect ELISA |
| ADB-BY17 | Adalimumab F(ab')2 | Neutralizing Antibody | / | PK bridging ELISA with ADB-Y23b |
| CEB-Y27 | Cetuximab F(ab')2 | Neutralizing Antibody | 0.007 |
ADA assay Neutralizing assay Indirect ELISA |
| CEB-Y28 | Cetuximab F(ab')2 | Neutralizing Antibody | 0.0015 |
ADA assay Neutralizing assay Indirect ELISA |
| CEB-Y29 | Cetuximab F(ab')2 | Neutralizing Antibody | / |
PK bridging ELISA with CEB-BY31 Neutralizing assay Indirect ELISA |
| CEB-Y31 | Cetuximab F(ab')2 | Non-Neutralizing Antibody | 0.421 |
ADA assay Indirect ELISA |
| CEB-BY31 | Cetuximab F(ab')2 | Non-Neutralizing Antibody | / | PK bridging ELISA with CEB-Y29 |
| RIB-Y36 | Rituximab F(ab')2 | Neutralizing Antibody | 0.01 |
ADA assay Neutralizing assay Indirect ELISA |
| RIB-Y37 | Rituximab F(ab')2 | Neutralizing Antibody | / |
PK bridging ELISA Neutralizing assay Indirect ELISA |
| BEB-Y12 | Bevacizumab F(ab')2 | Neutralizing Antibody | 0.0828 |
Neutralizing assay Indirect ELISA |
| BEB-Y9 | Bevacizumab F(ab')2 | Neutralizing Antibody | 1.92 |
ADA assay Indirect ELISA |
| BEB-Y10 | Bevacizumab F(ab')2 | Neutralizing Antibody | / |
PK bridging ELISA with BEB-BY13 Neutralizing assay Indirect ELISA |
| BEB-BY13 | Bevacizumab F(ab')2 | Neutralizing Antibody | / | PK bridging ELISA with BEB-Y10 |
Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized rituximab at 1 µg/ml, added increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 10% human serum) and then added biotinylated rituximab at 2 µg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.
Anti-Rituximab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Rituximab at 5 µg/mL, SULFO-Rituximab at 5Nµg/mL and increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.
s
Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized adalimumab at 1 µg/ml, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL.
Comparison between anti-idiotypic capture ELISA and anti-idiotypic bridging ELISA for rituximab detection in patient samples. Left: anti-idiotypic capture ELISA; Right: anti-idiotypic bridging ELISA.
Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y37) at 2 μg/ml, added increasing concentrations of Rituximab (10% human serum) and then added biotinylated Anti-Rituximab Antibodies (Cat. No. RIB-BY35) at 1 μg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/ml.
Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.
Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.
Reconstituted Anti-Trastuzumab Antibodies were diluted to 0.4 mg/ml, aliquoted and placed at 37°C. Aliquots were removed from 37°C at every time and placed at 4°C along with the control. No significant loss of activity was observed.
Anti-Trastuzumab Antibodies were subjected to the indicated number of freeze-thaw cycles (FT). No significant loss of activity was observed.
